MedTrace Logo

A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

NCT07030699 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2026-04-07

No results posted yet for this study

Summary

The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL. This is the first time the combination of drugs is being tested.

Conditions

Interventions

DRUG

Epcoritamab

Subcutaneous, once weekly in cycles 1-3; every 4 weeks cycles 4-12

DRUG

Lenalidomide

Oral, daily on days 1-21 of a 28-day cycle

DRUG

Tafasitamab

Intravenous, once weekly during cycles 1-3, then every 2 weeks during cycle 4-12

Sponsors & Collaborators

Principal Investigators

  • Pallawi Torka, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-13
Primary Completion
2026-03-31
Completion
2026-03-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07030699 on ClinicalTrials.gov